Serum Institute of India Pvt. Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Serum Institute of India Pvt. Ltd.
India’s healthcare and life sciences segment saw deals worth over $3bn in Q2 2023 turbocharged by private equity activity in the hospitals space and smaller biopharma acquisitions. Watch the APIs and brands space for heightened M&A action, say experts.
Merck Life Science’s top executives in India tell Scrip how they are helping biologics companies in APAC on their mRNA therapy journey. In the wide-ranging discussion, use of AI, the startup environment for biotechs and the changing face of manufacturing in India also came up.
Scrip delves into some of India’s critical compliance and quality challenges and efforts to address those.
Biocon subsidiary Syngene and Strides associate Stelis have entered a deal with the potential to change India’s vaccines and biologics landscape, as the former's growth plans are catapulted. Meanwhile, the Strides group gets to cut debt by selling a unit that made the ill-fated Sputnik Light COVID-19 vaccine and after Akston Biosciences terminated another COVID-19 vaccine alliance
- Large Molecule
- Other Names / Subsidiaries
- Bilthoven Biologicals
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.